Streetbeat News

BAYRY

Bayer AG

https://www.bayer.de/

CEO

Werner Baumann

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

6.48

Mkt cap

25B

Volume

94K

High

6.48

P/E Ratio

-19.55

52-wk high

11.33

Low

6.44

Div yield

0.00

52-wk low

6.39

Bayer AG has submitted a marketing authorization application to the European Medicines Agency for its menopause drug elinzanetant, following positive Phase 3 trial results. The drug showed significant reduction in vasomotor symptoms and improved quality of life over 52 weeks.

Portfolio Pulse from Vandana Singh

October 15, 2024 | 1:26 pm

Bayer AG has submitted an application to the European Medicines Agency for the approval of darolutamide, an oral androgen receptor inhibitor, for use in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. The application is based on positive Phase III ARANOTE trial results.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 3:34 pm

Bayer AG announced positive results from the Phase 3 ARANOTE trial for its prostate cancer drug, darolutamide, showing a significant reduction in the risk of radiological progression or death. Bayer plans to seek expanded use approval globally. The drug, marketed as Nubeqa, has shown consistent benefits across various patient subgroups and has low incidences of adverse events.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 3:11 pm

Roivant Sciences Ltd. has launched a new subsidiary, Pulmovant, to develop and commercialize the pulmonary hypertension drug mosliciguat, in-licensed from Bayer AG. The drug has shown promising results in reducing pulmonary vascular resistance in trials. Roivant's stock is down 1.88% following the announcement.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:21 pm

BridgeBio Pharma's stock rose after presenting positive data from its Phase 3 study of acoramidis for ATTR-CM at the ESC 2024. The company has submitted a marketing application to the FDA, with a decision expected by November 29, and to the European Medicines Agency, with a decision in 2025. BridgeBio has also partnered with Bayer for commercialization in Europe.

Portfolio Pulse from Vandana Singh

August 30, 2024 | 5:10 pm

An Australian judge dismissed a class action lawsuit alleging Bayer's Roundup weedkiller causes blood cancer, marking a significant victory for Bayer. The ruling supports Bayer's stance on the safety of its glyphosate-based products. Despite this win, Bayer still faces over 50,000 claims in the U.S.

Portfolio Pulse from Vandana Singh

July 25, 2024 | 6:35 pm

A Pennsylvania judge reduced a $2.25 billion verdict against Bayer AG to $400 million in a case involving cancer claims linked to Roundup weedkiller. Bayer plans to appeal the decision, while the plaintiff's legal team seeks to reinstate the original verdict. Despite numerous studies indicating glyphosate's safety, Bayer faces extensive legal challenges and over 50,000 pending claims.

Portfolio Pulse from Vandana Singh

June 05, 2024 | 2:06 pm

European equities closed higher on Monday, driven by expectations of an imminent ECB rate cut. Key ECB members made statements supporting a rate cut in June. The euro inched higher, and major European indices saw gains. Notable stock movers included RWE AG, Bayer AG, Volkswagen AG, Enel, Iberdrola, Eni, Novo Nordisk, LVMH, ASML, Stellantis, Ferrari, and UBS.

Portfolio Pulse from Piero Cingari

May 27, 2024 | 5:55 pm

Cencora Inc (NYSE:COR) has notified individuals about a data breach that occurred in February, compromising sensitive medical information. The breach involved data obtained through partnerships with pharmaceutical companies such as AbbVie Inc (NYSE:ABBV), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), Bayer AG (OTC:BAYZF, OTC:BAYRY), Novartis AG (NYSE:NVS), and Regeneron Pharmaceuticals Inc (NASDAQ:REGN). The incident is part of a series of cyberattacks targeting the U.S. healthcare sector.

Portfolio Pulse from Vandana Singh

May 24, 2024 | 4:00 pm

Pfizer, AstraZeneca, Sanofi, and other pharmaceutical companies are investing heavily in France to expand their operations. Pfizer and AstraZeneca will invest nearly $1 billion combined, while Sanofi will invest $1.1 billion. Other companies like AbbVie, Novartis, and Kenvue are also increasing their presence in France. Additionally, Mainz Biomed is expected to unveil breakthrough early cancer detection results in the US.

Portfolio Pulse from Upwallstreet

May 16, 2024 | 12:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.